PFG Investments LLC Has $318,000 Stake in GSK plc (NYSE:GSK)

PFG Investments LLC reduced its stake in GSK plc (NYSE:GSK) by 52.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,594 shares of the pharmaceutical company’s stock after selling 9,654 shares during the period. PFG Investments LLC’s holdings in GSK were worth $318,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of GSK. Fairfield Bush & CO. acquired a new position in shares of GSK in the first quarter valued at $80,000. JPMorgan Chase & Co. increased its holdings in shares of GSK by 2.3% in the first quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock valued at $10,514,000 after purchasing an additional 5,518 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of GSK in the first quarter valued at about $467,000. Blair William & Co. IL grew its stake in shares of GSK by 3.0% in the first quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock valued at $1,620,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of GSK by 2.4% in the first quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock valued at $2,744,000 after acquiring an additional 1,453 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on GSK shares. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Morgan Stanley assumed coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy”.

GSK Stock Down 0.3 %

GSK stock opened at $42.86 on Friday. The stock has a market capitalization of $88.22 billion, a P/E ratio of 14.24, a price-to-earnings-growth ratio of 1.94 and a beta of 0.64. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84. The firm has a 50-day moving average price of $41.62 and a 200-day moving average price of $38.35.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. As a group, equities research analysts anticipate that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Investors of record on Friday, February 23rd will be issued a $0.3564 dividend. This represents a $1.43 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio (DPR) is 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.